Jean Gariepy

Toronto, ON M5S3M2, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis.

An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis.

Journal: Investigative ophthalmology & visual science

Published: May 15, 2026

Human MAdCAM-1 antibodies as targeted immune modulators.

Human MAdCAM-1 antibodies as targeted immune modulators.

Journal: Scientific reports

Published: April 01, 2025

Broadly Applicable Bispecific Linker Approach to Noncovalently Target Therapeutic Nanoparticles to Tumor Cells Expressing Carcinoembryonic Antigen.

Broadly Applicable Bispecific Linker Approach to Noncovalently Target Therapeutic Nanoparticles to Tumor Cells Expressing Carcinoembryonic Antigen.

Journal: ACS pharmacology & translational science

Published: March 13, 2024

Emerging insights into ethnic-specific TP53 germline variants.

Emerging insights into ethnic-specific TP53 germline variants.

Journal: Journal of the National Cancer Institute

Published: February 14, 2023

Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics.

Labeling Cell Surface Receptors with Ligand.BirA* Bispecifics.

Journal: ACS pharmacology & translational science

Published: February 06, 2023

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity.

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity.

Journal: Scientific reports

Published: September 13, 2022

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.

Journal: Signal transduction and targeted therapy

Published: July 01, 2022

Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?

Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?

Journal: Frontiers in immunology

Published: December 16, 2021

VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils.

VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils.

Journal: Cellular immunology

Published: December 07, 2021

Agonistic nanobodies and antibodies to human VISTA.

Agonistic nanobodies and antibodies to human VISTA.

Journal: mAbs

Published: November 24, 2021

Author Correction: Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhances their intracellular delivery and photodynamic killing of cancer cells.

Author Correction: Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhances their intracellular delivery and photodynamic killing of cancer cells.

Journal: Scientific reports

Published: October 31, 2020

A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells.

A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells.

Journal: JCI insight

Published: June 12, 2020

Showing 1-12 of 36

Last Updated: 09/26/2026